



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرو فيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Recurrence Rate of Hepatocellular Carcinoma after Treatment of Chronic Hepatitis C Patients with Direct Acting Antivirals: Randomized Controlled Phase 3 Trial (Cautious Trial)

Thesis

*Submitted for Partial Fulfillment of M.D.
in Clinical Oncology & Nuclear Medicine*

By

Fatma Sayed Mohamed Abdelbakey

Master Degree

Under Supervision of

Prof. Hesham Ahmed Elghazaly

Professor of Clinical Oncology and Nuclear Medicine

Faculty of Medicine, Ain Shams University

Prof. Mohamed Kamal Shaker

Professor of Hepatology and Tropical Medicine

Faculty of Medicine, Ain Shams University

Assistant Prof. Khaled Naguib Abdelhakim

Assistant Professor of Clinical Oncology and Nuclear Medicine

Faculty of Medicine, Ain Shams University

Assistant Prof. Nagy Samy Gobran

Assistant Professor of Clinical Oncology and Nuclear Medicine

Faculty of Medicine, Ain Shams University

Dr. Reham Mohamed Faheim

Lecturer of Clinical Oncology and Nuclear Medicine

Faculty of Medicine, Ain Shams University

Faculty of Medicine, Ain Shams University

2021

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سَبَّحَانَكَ لَا إِلَهَ إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Hesham Ahmed Elghazaly**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for his meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Prof. Mohamed Kamal Shaker**, Professor of Hepatology and Tropical Medicine, Faculty of Medicine, Ain Shams University, for his sincere efforts, fruitful encouragement.*

*Really I can hardly find the words to express my gratitude to **Assistant Prof. Khaled Maguib Abdelhakim**, Assistant Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for his supervision, continuous help, encouragement throughout this work*

*I am deeply thankful to **Assistant Prof. Magy Samy Gobran**, Assistant Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for his great help, outstanding support, active participation and guidance.*

*Last but not least my sincere thanks and appreciation to **Dr. Reham Mohamed Faheim**, Lecturer of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for her tremendous effort, he has done in the meticulous revision of the whole work.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Fatma Sayed Mohamed Abdelbakey

List of Contents

Title	Page No.
List of Tables.....	i
List of Figures	ii
List of Abbreviations.....	iv
Introduction	1
Aim of the Work	4
Review of Literature	
Epidemiology and Surveillance.....	5
Etiology and Risk Factors	16
Hepatitis C Virus	30
Diagnosis.....	43
Management	60
Correlation between DAA and HCC Recurrence	79
Patients and Methods.....	94
Results.....	98
Discussion	113
Summary	129
Conclusion	131
References	132
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table 1:	Risk factors for HCC development.....	18
Table 2:	Diagnostic work-up.....	43
Table 3:	CT/MRI diagnostic table.....	48
Table 4:	Child-Pugh score.....	54
Table 5:	AJCC 8 th edition TNM staging of HCC.....	56
Table 6:	Various extended criteria for HCC and liver transplantation	63
Table 7:	Phase II or III trials testing neoadjuvant and/or adjuvant strategies before/following effective curative procedures (resection or percutaneous ablation)	72
Table 8:	List of trials of targeted therapy in advanced HCC.....	77
Table 9:	Baseline characteristics, at the time of HCC complete radiological response between the two arms.....	101
Table 10:	DAA treatment regimens and SVR12 proportions in the DAA-treated arm (N = 40)	104
Table 11:	Prognostic factors of HCC TTR	111
Table 12:	Prognostic factors of overall survival.....	112
Table 13:	Studies showed increase of HCC recurrence after DAA therapy	119
Table 14:	Studies showed no increase of HCC recurrence after DAA therapy	121

List of Figures

Fig. No.	Title	Page No.
Figure 1:	Number of new cases of HCC in 2020.....	5
Figure 2:	Number of deaths of HCC in 2020	6
Figure 3:	Number of new HCC cases in Egypt, in 2020, both sexes, all ages	9
Figure 4:	Age-standardized incidence and mortality rates of HCC in Egypt	10
Figure 5:	HCV genotype distribution by Global Burden of Disease (GBD) region.	32
Figure 6:	Sources of HCV infection.....	34
Figure 7:	Hepatitis C virus lifecycle	37
Figure 8:	Simplified overview of the sites of DAA therapies	39
Figure 9:	Summary of HCV history and treatments	40
Figure 10:	DAAs combination since 2013.....	41
Figure 11:	CT/MRI LI-RADS® v2018.....	47
Figure 12:	HCC typical criteria in multiphasic CECT.....	48
Figure 13:	Typical enhancement pattern and temporal presentation of HCC and ICC in the dynamic CEUS examination	49
Figure 14:	HCC: CEUS enhancement in the arterial, portal-venous and late phase after administration of SonoVue®	50
Figure 15:	Comparative pathological features of dysplastic nodules and highly differentiated HCC.....	52
Figure 16:	BCLC staging system and treatment strategy....	57

List of Figures cont...

Fig. No.	Title	Page No.
Figure 17:	Study profile.....	100
Figure 18:	2-year, 3-year RR (red arrow), median TTR (black arrow): Arm 1 vs Arm 2	102
Figure 19:	2-year, 3-year RR (red arrow), median TTR (black arrow) in Arm 1: SVR vs no-SVR	105
Figure 20:	2-year, 3-year RR (red arrow), median TTR (black arrow): Arm 1A vs Arm1B vs Arm 2	106
Figure 21:	2-year, 3-year RR (red arrow), median TTR (black arrow): Arm 1A vs Arm 1B1 vs Arm 1B2 vs Arm 2	107
Figure 22:	Median OS: Arm 1 vs Arm 2	108
Figure 23:	Median OS in Arm 1: SVR vs no-SVR	109
Figure 24:	Median OS: Arm 1A vs Arm1B vs Arm 2	109
Figure 25:	Median OS: Arm 1A vs Arm 1B1 vs Arm 1B2 vs Arm 2	110

List of Abbreviations

Abb.	Full term
A1ATD	α 1-Antitrypsin deficiency
AASLD	American Association for the Study of Liver Diseases
AFB1.....	Aflatoxin B1
AFP	Alpha-fetoprotein
AGA	American Gastroenterology Association
AHPBA	Americas Hepato-Pancreato-Biliary Association
AIH	Autoimmune hepatitis
AJCC	American Joint Committee on Cancer
ALBI	Albumin-bilirubin
ASIRS.....	Age-standardized incidence rates
BCLC	Barcelona Clinic Liver Cancer
CECT	Contrast-enhanced computed tomography
CEMRI	Contrast-enhanced magnetic resonance imaging
CEUS	Contrast-enhanced US
CI	Confidence interval
CLIP	Cancer of the Liver Italian Program
CT	Computed tomography
DAA	Direct-acting antiviral
EASL	European Association for the Study of the Liver
EGFR	Epidermal growth factor receptor
EOT	End of therapy
FDG-PET	Fluorodeoxyglucose-positron emission tomography
GALC	German Alliance for Liver Cancer

List of Abbreviations *cont...*

Abb.	Full term
HBV	Hepatitis B virus
HCC	Hepatocellular carcinoma
HCV	Hepatitis C virus
HLA	Human leukocyte antigen
HR	Hazard ratio
IBT	Interferon based therapy
ICC	Intrahepatic cholangiocarcinoma
IFN	Interferon
IGF-1	Insulin like growth factor-1
IL	Interleukin
IRE	Irreversible electroporation
JIS	Japanese Integrated Staging
LI-RADS	Liver Imaging Reporting and Data System
LMICs	Lower-middle income countries
LOD	Limit of detection
mRECIST	Modified Response Evaluation Criteria in Solid Tumors
MRI	Magnetic resonance imaging
MSM	Men who have sex with men
MWA	Microwave ablation
NAFLD	Non-alcoholic fatty liver disease
NASH	Non-alcoholic steatohepatitis
ORR	Objective response rate
OS	Overall survival
PS	Performance status
PWID	People who inject drugs
rCR	Radiological complete response
RFA	Radiofrequency ablation

List of Abbreviations *cont...*

Abb.	Full term
RFS	Recurrence-free survival
RR	Recurrence Rate
SVR	Sustained virological response
TACE	Trans-arterial chemoembolization
TKI	Tyrosine kinase inhibitors
TNM	Tumor, Node, Metastasis
TTR	Time to recurrence
UICC	Union for International Cancer Control
UNOS	United Network for Organ Sharing
WHO	World health organization

INTRODUCTION

Hepatocellular carcinoma (HCC) represents about 75–85% of primary liver cancers ⁽¹⁾, it is the sixth most common cancer and the third leading cause of cancer-related death worldwide ⁽²⁾. Whereas in Egypt, it represents the most commonly diagnosed cancer, with about 27,895 new case in 2020 ⁽³⁾, a consequence of the high prevalence of hepatitis C virus (HCV) infection in Egypt ⁽⁴⁾, with an estimated 10% of the total population were seropositive for HCV antibodies and 7% had viremia as reported in the Egyptian Demographic and Health Survey (DHS) of 2015, what constitutes a major health and economic burden ⁽⁵⁾.

HCV genotype 4 is considered the most predominant genotype in Egypt ⁽⁶⁾, with about 10–20% of individuals with chronic HCV infection has complications, including decompensated cirrhosis and HCC, over a period of 20–30 years ⁽⁷⁾. When liver cirrhosis is established, the 5-year risk of HCC occurrence is approximately 13% in those with cirrhosis ⁽⁸⁾. However, our map and records of HCV, and viral hepatitis in general, have recently some changes owing to the immigration to Egypt after revolutions and wars in the Middle Eastern countries in the recent years, so screening for immigrants regarding the HCC risk factors, in general, and both Hepatitis B virus (HBV) and HCV, in particular, should be encouraged ⁽⁹⁾.

With the introduction of the direct-acting antiviral (DAA) agents in 2014 as an effective HCV treatment, the National Committee for Control of Viral Hepatitis (NCCVH) started a national program to make HCV treatment available for all and covered by the Egyptian government ⁽¹⁰⁾, therefore, by 2018 40% of the total HCV-infected population were treated (about more than 2 million patients), with sustained virological response (SVR) rate above 90% ⁽⁴⁾. This in line with the World health organization (WHO) global hepatitis strategy to eradicate viral hepatitis by 2030 ⁽¹¹⁾.

Chronic HCV patients with prior history of HCC was a challenging situation in HCV treatment, our NCCVH recommended to receive DAA after more than 4 weeks of HCC treatment and achieving radiological complete response (rCR) ⁽¹²⁾. Although many studies proved reduced HCC occurrence and recurrence after interferon based therapy (IBT), it was unclear if this the same benefit would be seen with DAAs ⁽¹³⁾.

Early reports showed high HCC recurrence rate (RR) after DAA in chronic HCV patients with prior history of DAA ⁽¹⁴⁻²³⁾, which followed by other studies reported contradictory results that DAA did not increase the HCC recurrence ⁽²⁴⁻³³⁾, meanwhile some studies revealed that DAA associated with decrease HCC RR ⁽³⁴⁻⁴¹⁾.

Therefore, a constant debate is still ongoing and the evidence is yet unclear whether DAA therapy may increase